Table 2.
Effects of cannabis on TMS measures.
| Study. | AMT | RMT | MEP | CSP | iSP | SAI | LAI | SICI | ICF | SICF | LICI | SIHI | LIHI | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hasan et al. [104] | – | ○ | ○ | ▲ | – | – | – | ▲ | – | – | – | – | – | Acute intake |
| Fitzgerald et al. [105] | ○ | ○ | ○ | ○ | – | – | – | ▼ | ○ | – | ○ | – | – | Heavy and light cannabis users vs. non-users |
| Martin-Rodriguez et al. [106] | ○ | ○ | ○ | – | – | – | – | ▼ | – | – | – | – | – | CUD and daily cannabis users vs. non-users |
| Wobrock et al. [107] | – | ○ | – | – | – | – | – | ▼ | ▲ | – | – | – | – | Schizophrenia cannabis users vs. non-users |
| Flavel et al. [108] | – | ○ | ○ | ○ | – | – | – | – | – | ○ | ○ | – | – | Cannabis users vs. nonusers |
| Goodman et al. [109] | – | ○ | – | ○ | – | – | – | ▲ | ○ | – | ○ | – | – | Schizophrenia cannabis users vs. non-users |
| – | ○ | – | ○ | – | – | – | ▼ | ○ | – | ○ | – | – | Control cannabis users vs. nonusers | |
| Russo et al. [110] | ○ | ○ | ○ | ○ | – | ○ | ○ | ▲ | ▼ | – | – | – | – | MS patients on 1 month of Sativex |
| Leocani et al. [111] | – | ○ | ○ | – | – | – | – | ○ | ○ | – | – | – | – | MS patients on 1 month of Sativex |
| Calabrò et al. [112] | – | – | ▲ | – | – | – | – | ▼ | ▼ | – | – | – | – | MS patients on 6 weeks of Sativex + gait training |
▲ increase; ▼decrease; ○ indicates no change; – indicates did not assess; CUD: cannabis use disorder; MS: multiple sclerosis.